LYTIR

Company · KROS

Keros Therapeutics, Inc.

Nasdaq's symbol directory lists KROS on Nasdaq as “Keros Therapeutics, Inc. - common stock”.

In the 12 months to Nov 8, 2026: insiders bought on 3 occasions ($31K); insiders sold on 5 occasions ($107K); 3 filings by holders of 5% or more; 4 company reports (Form 8-K, since May 26, 2026).

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $31K in total; Insider sales: $107K in total.Jun: Insider purchases $10KJun: Insider sales $6KJul: Insider purchases $11KAug: Insider purchases $10KAug: Insider sales $101KDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $31KInsider sales below: $107K
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Cho Esther, Chief Legal Officer sold on 1 day latest Aug 18, 2026 sold $46K
  2. Lerner Lorena Raquel, Chief Scientific Officer sold on 1 day latest Aug 18, 2026 sold $37K
  3. Jean J. Bienaime bought on 3 days latest Aug 17, 2026 bought $31K
  4. Tanini Annita, Corp. Controller & VP, Finance sold on 1 day latest Aug 18, 2026 sold $13K
  5. Newton Charles W. sold on 2 days all under a 10b5-1 plan latest Aug 18, 2026 sold $11K
Every trade (8)
  1. SELLCho Esther, Chief Legal Officer sold Aug 18, 2026 4,485 shares filing $46K
  2. SELLLerner Lorena Raquel, Chief Scientific Officer sold Aug 18, 2026 3,568 shares filing $37K
  3. SELLTanini Annita, Corp. Controller & VP, Finance sold Aug 18, 2026 1,224 shares filing $13K
  4. SELLNewton Charles W. sold Aug 18, 2026 551 shares 10b5-1 plan (scheduled) filing $6K
  5. BUYJean J. Bienaime bought Aug 17, 2026 1,000 shares 10b5-1 plan (scheduled) filing $10K
  6. BUYJean J. Bienaime bought Jul 15, 2026 1,000 shares 10b5-1 plan (scheduled) filing $11K
  7. BUYJean J. Bienaime bought Jun 15, 2026 1,000 shares 10b5-1 plan (scheduled) filing $10K
  8. SELLNewton Charles W. sold Jun 11, 2026 550 shares 10b5-1 plan (scheduled) filing $6K

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. BlackRock Portfolio Management LLC filed Oct 27, 2026 Schedule 13G/A passive 1,813,870 shares filing 9.1%
  2. BlackRock, Inc. filed Jul 29, 2026 Schedule 13G/A passive 1,671,343 shares filing 8.4%
  3. BlackRock Portfolio Management LLC filed Jul 17, 2026 Schedule 13G passive 1,122,874 shares filing 5.7%

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Regulation FD disclosure filing Nov 5, 2026
  2. Results of operations and financial condition filing Nov 5, 2026
  3. Regulation FD disclosure filing Sep 29, 2026
  4. Regulation FD disclosure filing Sep 28, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.